Revision history of "Increase in R & D capacity in Exbio Praha" (Q9626)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

22 March 2024

15 January 2024

11 June 2023

17 February 2023

26 July 2022

  • curprev 09:0109:01, 26 July 2022DG Regio talk contribs 48,685 bytes +28,075 Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, pl, sl, lt, lv, bg, hu, ga, sv, et, cs, nl, fr, de, it, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, pl, sl, lt, lv, bg, hu, ga, sv, et,

24 June 2022

24 February 2022

15 January 2022

14 January 2022

12 December 2021

2 December 2021

  • curprev 07:4707:47, 2 December 2021DG Regio talk contribs 16,913 bytes +1,423 Created claim: summary (P836): Ziel des Projekts ist es, die Kapazitäten des eigenen F & E-Unternehmens Exbio Praha, a.s. hauptsächlich auf dem Gebiet der neuen monoklonalen Antikörper und deren Derivate, direkt markierte monoklonale Antikörper für den Einsatz in der Strömungszytometrie, zu erhöhen. Diese dienen der Weiterentwicklung neuer Diagnosekits für den Einsatz in diagnostischen (menschlichen Modellen) oder wissenschaftlichen Laboren (Tiermodell). Die Lösung der Projek...
  • curprev 07:4707:47, 2 December 2021DG Regio talk contribs 15,490 bytes +105 Changed label, description and/or aliases in de: translated_label

28 November 2021

  • curprev 07:2307:23, 28 November 2021DG Regio talk contribs 15,385 bytes +1,483 Created claim: summary (P836): L’objectif du projet est d’augmenter les capacités de sa propre société de R & D Exbio Praha, a.s. principalement dans le domaine des nouveaux anticorps monoclonaux et de leurs dérivés, des anticorps monoclonaux directement marqués pour une utilisation en cytométrie de flux. Ceux-ci serviront à la poursuite du développement de nouveaux kits de diagnostic destinés à être utilisés dans des laboratoires de diagnostic (modèle humain) ou scientifique...
  • curprev 07:2307:23, 28 November 2021DG Regio talk contribs 13,902 bytes +113 Changed label, description and/or aliases in fr: translated_label

27 December 2020

28 October 2020

22 October 2020

  • curprev 14:5214:52, 22 October 2020DG Regio talk contribs 14,243 bytes +1,341 Created claim: summary (P836): The aim of the project is to increase the capacity of the R & D of Exbio Praha, a.s., especially in the field of new monoclonal antibodies and their derivatives, directly labelled monoclonal antibodies for use in flow cytometry. These will serve for further development of new diagnostic kits for use in diagnostic (human model) or scientific laboratories (animal model). Resolving the project objectives will enable the company to develop a portfol...
  • curprev 14:5214:52, 22 October 2020DG Regio talk contribs 12,902 bytes −893 Removed claim: summary (P836): The aim of the project is to increase the capacity of the R & D of Exbio Praha, a.s., especially in the field of new monoclonal antibodies and their derivatives, directly labelled monoclonal antibodies for use in flow cytometry. These will serve for further development of new diagnostic kits for use in diagnostic (human model) or scientific laboratories (animal model). Resolving the project objectives will enable the company to develop a portf...
  • curprev 06:3106:31, 22 October 2020DG Regio talk contribs 13,795 bytes +100 Changed label, description and/or aliases in 1 language: translated_label
  • curprev 06:3106:31, 22 October 2020DG Regio talk contribs 13,695 bytes −100 Changed label, description and/or aliases in 1 language: remove_english_label

2 September 2020

  • curprev 07:2107:21, 2 September 2020DG Regio talk contribs 13,795 bytes +893 Created claim: summary (P836): The aim of the project is to increase the capacity of the R & D of Exbio Praha, a.s., especially in the field of new monoclonal antibodies and their derivatives, directly labelled monoclonal antibodies for use in flow cytometry. These will serve for further development of new diagnostic kits for use in diagnostic (human model) or scientific laboratories (animal model). Resolving the project objectives will enable the company to develop a portfol...

15 July 2020

19 June 2020

6 June 2020

25 March 2020

19 March 2020

3 March 2020

11 February 2020

30 January 2020

28 January 2020

16 January 2020

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)